XOMA Ltd. has made four senior management appointments. Appointments include Robert H. Gundel, Ph.D., vice president, scientific corporate development; Mary Haak-Frendscho, Ph.D., vice president, preclinical R&D; Mark White, vice president, cell and analytical development; and Paul Goodson, senior director, investor relations.

In his new role, Dr. Gundel provides corporate leadership to key areas of XOMA’s business, including corporate messaging, business development and specialized projects. Dr. Gundel has more than 20 years experience in the biotechnology and pharmaceutical industries including management positions at Chiron Corp., Boehringer Ingelheim Pharmaceuticals, and Bayer Corp. He joined XOMA in 2002 and most recently served as the company’s vice president, preclinical development.

As vice president, preclinical R&D, Dr. Haak-Frendscho leads XOMA’s antibody platform enhancement effort and directs the antibody discovery and preclinical development of the company’s drug candidates. She has more than 15 years experience in the biotechnology industry. She joined the company in 2003 as senior director, cell and analytical biology.

Mr. White was appointed vice president, cell and analytical development in November 2005. In his new role, Mr. White provides strategic leadership in developing and implementing the company’s cell expression and pharmaceutical/bioanalytical capabilities. Mr. White’s career at XOMA spans 15 years and includes multiple scientific and management positions with increasing responsibility. Most recently he was senior director, cell and analytical development, where he successfully integrated the company’s cell biology and pharmaceutical development groups.

Paul Goodson, an investor relations executive, has more than 20 years of investor relations and general management experience. He joins the company from Shareholder Value Partners, a consulting firm he founded in 2003. Prior to that Mr. Goodson was vice president of investor relations at Invitrogen Corp., and was previously president of two R&D firms.